A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Exclusion Criteria

• •Primary brain tumors or known active brain metastases, leptomeningeal, or cranial epidural disease.
• •History of interstitial lung disease (ILD) of any grade or history of organizing pneumonia.
• •Has acute ocular infection, acute or chronic ulcerative/cicatricial condition of conjunctiva or cornea.
• •Known history of immunodeficiency virus (HIV) unless specific criteria are met.
• •Active infection with hepatitis C virus (HCV) defined as positive for HCV antibody.
• •Major surgery within 4 weeks before the first dose of study treatment.
• •Received radiation therapy within 2 weeks before the first dose of study treatment.
• •Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study treatment.